Department of Pathology and Molecular Pathology, Johannes Kepler University Linz, Kepler University Hospital GmbH, Altenberger Straße 69 and Krankenhausstraße 9, 4040, Linz, Austria.
Pathology Institute Enge, Hardturmstrasse 133, 8005, Zurich, Switzerland.
Hum Pathol. 2024 Oct;152:105640. doi: 10.1016/j.humpath.2024.105640. Epub 2024 Aug 10.
The impact of special histological types (ST) in triple-negative breast cancer (TNBC) and its association with overall outcome has gained increasing relevance as survival has been linked to specific histological TNBC subtypes. We evaluated the clinicopathological and survival data of 598 patients with 613 TNBCs, including 464 TNBCs of no special type (NST) and 149 TNBCs ST (low-grade, n = 12, 8.1%; high-grade, n = 112, 75.2%; apocrine and androgen receptor-positive [APO AR], n = 25, 16.8%). Patients with low-grade TNBC ST and TNBC ST APO AR were significantly older (P < 0.001) and had a lower Ki67 index (P < 0.001) than those with TNBC NST. Patients with high-grade TNBC ST were significantly older (P = 0.006) and had poorer pathological responses to neoadjuvant chemotherapy (NAC) (P < 0.001) than those with TNBC NST. Significant survival differences were observed between low-grade TNBC ST, TNBC ST APO AR, high-grade TNBC ST, and TNBC NST in the entire study group (DFS, P = 0.002; DDFS, P = 0.001) and in the non-NAC subgroup (OS, P = 0.034; DFS, P = 0.001; DDFS, P < 0.001). Patients with low-grade TNBC ST had the best survival outcomes. Patients with high-grade TNBC ST showed significantly worse outcomes than those with TNBC NST (entire study group: OS, P = 0.049; DFS, P < 0.001; DDFS, P = 0.001; non-NAC subgroup: OS, P = 0.014; DFS, P < 0.001; DDFS, P < 0.001). We conclude that prognostic stratification of TNBC ST is ultimately important for optimizing the therapeutic management of patients with these rare tumor entities.
特殊组织学类型 (ST) 在三阴性乳腺癌 (TNBC) 中的影响及其与总体预后的相关性日益受到关注,因为生存与特定的 TNBC 组织学亚型相关。我们评估了 598 例 613 例 TNBC 患者的临床病理和生存数据,其中 464 例 TNBC 为非特殊类型 (NST),149 例 TNBC 为 ST (低级别,n=12,8.1%;高级别,n=112,75.2%;大汗腺癌和雄激素受体阳性 [APO AR],n=25,16.8%)。低级别 TNBC ST 和 TNBC ST APO AR 患者明显比 TNBC NST 患者年龄更大 (P<0.001),Ki67 指数更低 (P<0.001)。高级别 TNBC ST 患者明显比 TNBC NST 患者年龄更大 (P=0.006),对新辅助化疗 (NAC) 的病理反应更差 (P<0.001)。在整个研究组 (DFS,P=0.002;DDFS,P=0.001) 和非 NAC 亚组 (OS,P=0.034;DFS,P=0.001;DDFS,P<0.001) 中,低级别 TNBC ST、TNBC ST APO AR、高级别 TNBC ST 和 TNBC NST 之间观察到显著的生存差异。低级别 TNBC ST 患者的生存结果最好。高级别 TNBC ST 患者的生存结果明显比 TNBC NST 患者差 (整个研究组:OS,P=0.049;DFS,P<0.001;DDFS,P=0.001;非 NAC 亚组:OS,P=0.014;DFS,P<0.001;DDFS,P<0.001)。我们得出结论,对 TNBC ST 进行预后分层最终对优化这些罕见肿瘤实体患者的治疗管理至关重要。